Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pevonedistat - Takeda Oncology

Next Previous
X
Search
Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 24 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Case Western Reserve University; Children's Oncology Group; Eli Lilly and Company; Greehey Childrens Cancer Research Institute; Louisiana State University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Nationwide Children's Hospital; PETHEMA Foundation; Takeda Oncology; Translational Genomics Research Institute; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southampton; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Antirheumatics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Chronic myelomonocytic leukaemia; Glioblastoma; Lymphoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from a phase II trial in Acute myeloid leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 05 Apr 2024 Pharmacodynamics data from the preclinical trials in Solid tumours presented at the115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 09 Dec 2023 Efficacy, pharmacodynamics and adverse events data from the phase I/II trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top